SCHEMBL3289767

SCHEMBL3289767

CC1(O)CN(S(=O)(=O)c2ccc3c(C(=O)O)c[nH]c(=O)c3c2)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 5/20 0.51
▸ GAA P10253 5/20 0.51
▸ HPGD P15428 3/20 0.51
▸ MAPT P10636 2/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ HRH1 P35367 2/20 0.50
▸ CCR3 P51677 2/20 0.50
▸ KCNH2 Q12809 2/20 0.50
▸ KDM4E B2RXH2 7/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ POLB P06746 2/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ USP2 O75604 1/20 0.44
▸ PTPN7 P35236 1/20 0.44
▸ HTT P42858 1/20 0.42
▸ LMNA P02545 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ GLA P06280 2/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3282728 0.83 GAA (0.58) HSD17B10GAAHPGDMAPTCYP2C19
SCHEMBL2922964 0.77 KDM4E (0.54) HSD17B10GAAHPGDMAPTCYP2C19
SCHEMBL2922360 0.76 KDM4E (0.56) HSD17B10GAAHPGDMAPTCYP2C19
SCHEMBL2916302 0.74 KDM4E (0.54) HSD17B10GAAHPGDMAPTCYP2C19
SCHEMBL2920920 0.74 KDM4E (0.54) HSD17B10GAAHPGDMAPTCYP2C19
SCHEMBL2923292 0.74 KDM4E (0.50) HSD17B10GAAHPGDMAPTCYP2C19
SCHEMBL2913348 0.74 KDM4E (0.50) HSD17B10GAAHPGDMAPTCYP2C19
SCHEMBL2916325 0.72 KDM4E (0.54) HSD17B10GAAHPGDMAPTCYP2C19
SCHEMBL3282678 0.70 PARG (0.50) HSD17B10MAPTHRH1CCR3KCNH2
SCHEMBL20791101 0.70 MAPT (0.65) GAAMAPTKDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-20050107428-A1 Chemical compounds ASTRAZENECA AB (SE) 2005-05-19 — — US disclosed
EP-1478624-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2004-11-24 — — EP disclosed
WO-2003068743-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2003-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107428-A1 Chemical compounds CCR10, CCR3, CXCR5 HSD17B10 381/4885GAA 4864/4885HPGD 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback